JMP Group LLC (JMP)

SAN DIEGO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced its participation in the upcoming JMP Securities Hematology and Oncology Summit. Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in a virtual fireside chat at 2:00 p.m. ET / 11:00 a.m. PT on December 2, 2024.

Quadrant Capital Group LLC raised its holdings in Agree Realty Co. (NYSE:ADC – Free Report) by 35.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,079 shares of the real estate investment trust’s stock after buying an additional 1,074 shares during the quarter. Quadrant Capital Group LLC’s holdings in Agree Realty were worth $257,000 as of its most recent SEC filing. A number of other hedge funds also recently made changes to their positions in the business. HBC Financial Services PLLC acquired a new stake in shares of Agree Realty during the 4th quarter valued at about $31,000. Lindbrook Capital LLC lifted its stake in Agree Realty by 267.1% during the fourth quarter. Lindbrook Capital LLC now owns 591 shares of the real estate investment trust’s stock worth $37,000 after purchasing an additional 430 shares during the period. Jamison Private Wealth Management Inc. boosted its holdings in Agree Realty by 96.6% during the fourth quarter. Jamison Private Wealth Management Inc. now owns 741 shares of the real estate investment trust’s stock valued at $47,000 after purchasing an additional 364 shares in the last quarter. GAMMA Investing LLC bought a new stake in shares of Agree Realty in the 4th quarter valued at approximately $44,000. Finally, Blue Trust Inc. raised its holdings in shares of Agree Realty by 42.0% in the 4th quarter. Blue Trust Inc. now owns 1,255 shares of the real estate investment trust’s stock worth $79,000 after buying an additional 371 shares in the last quarter. Institutional investors and hedge funds own 97.83% of the company’s stock. Agree Realty Stock Performance Shares of Agree Realty stock opened at $60.53 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 0.71 and a quick ratio of 0.71. The firm has a 50 day simple moving average of $57.35 and a 200 day simple moving average of $58.74. Agree Realty Co. has a fifty-two week low of $52.69 and a fifty-two week high of $69.26. The firm has a market cap of $6.09 billion, a P/E ratio of 35.61, a P/E/G ratio of 2.78 and a beta of 0.52. Agree Realty Announces Dividend The company also recently announced a monthly dividend, which will be paid on Friday, June 14th. Stockholders of record on Friday, May 31st will be given a dividend of $0.25 per share. The ex-dividend date of this dividend is Thursday, May 30th. This represents a $3.00 dividend on an annualized basis and a dividend yield of 4.96%. Agree Realty’s payout ratio is currently 176.47%. Analysts Set New Price Targets Several brokerages recently commented on ADC. Mizuho boosted their price target on Agree Realty from $60.00 to $62.00 and gave the company a “neutral” rating in a research note on Friday, May 10th. Stifel Nicolaus lowered their target price on shares of Agree Realty from $70.00 to $69.50 and set a “buy” rating on the stock in a report on Wednesday, February 14th. Royal Bank of Canada dropped their target price on shares of Agree Realty from $67.00 to $63.00 and set an “outperform” rating for the company in a research report on Thursday, February 15th. JMP Securities raised shares of Agree Realty from a “market perform” rating to an “outperform” rating and set a $71.00 price objective on the stock in a research note on Monday, January 22nd. Finally, Wells Fargo & Company dropped their price objective on shares of Agree Realty from $66.00 to $62.00 and set an “overweight” rating for the company in a report on Tuesday, February 20th. Four research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $65.83. Read Our Latest Stock Analysis on ADC Insider Transactions at Agree Realty In other news, Chairman Richard Agree acquired 16,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was purchased at an average cost of $55.50 per share, for a total transaction of $888,000.00. Following the completion of the transaction, the chairman now directly owns 135,855 shares in the company, valued at $7,539,952.50. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Agree Realty news, Chairman Richard Agree bought 16,000 shares of the stock in a transaction on Thursday, February 29th. The stock was purchased at an average price of $55.50 per share, with a total value of $888,000.00. Following the acquisition, the chairman now owns 135,855 shares of the company’s stock, valued at $7,539,952.50. The purchase was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Joey Agree purchased 3,500 shares of the business’s stock in a transaction dated Wednesday, February 21st. The stock was bought at an average cost of $56.92 per share, for a total transaction of $199,220.00. Following the purchase, the chief executive officer now owns 561,403 shares in the company, valued at $31,955,058.76. The disclosure for this purchase can be found here. Insiders bought a total of 20,052 shares of company stock worth $1,117,942 over the last 90 days. 1.80% of the stock is owned by insiders. Agree Realty Profile (Free Report) Agree Realty Corporation is a publicly traded real estate investment trust that is RETHINKING RETAIL through the acquisition and development of properties net leased to industry-leading, omni-channel retail tenants. As of December 31, 2023, the Company owned and operated a portfolio of 2,135 properties, located in 49 states and containing approximately 44.2 million square feet of gross leasable area. Read More Five stocks we like better than Agree Realty Are These Liquid Natural Gas Stocks Ready For An Upside Bounce? Canada Goose Flies Higher Driven By DTC Growth Breakout Stocks: What They Are and How to Identify Them CVS Health Stock Has a Silver Lining Called Value What Are Dividend Champions? How to Invest in the Champions Magnificent 7 Still Magnificent as the Halfway Mark Approaches? Want to see what other hedge funds are holding ADC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agree Realty Co. (NYSE:ADC – Free Report).

Psagot Value Holdings Ltd. Israel trimmed its holdings in shares of Alphabet Inc. (NASDAQ:GOOGL – Free Report) by 0.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 64,070 shares of the information services provider’s stock after selling 358 shares during the quarter. Alphabet accounts for about 4.0% of Psagot Value Holdings Ltd. Israel’s portfolio, making the stock its 5th largest position. Psagot Value Holdings Ltd. Israel’s holdings in Alphabet were worth $8,981,000 as of its most recent SEC filing. Other hedge funds also recently added to or reduced their stakes in the company. RWQ Financial Management Services Inc. raised its position in shares of Alphabet by 8.2% in the 4th quarter. RWQ Financial Management Services Inc. now owns 61,499 shares of the information services provider’s stock valued at $8,591,000 after purchasing an additional 4,664 shares during the last quarter. Picton Mahoney Asset Management increased its stake in Alphabet by 55.4% during the 4th quarter. Picton Mahoney Asset Management now owns 214,443 shares of the information services provider’s stock valued at $29,956,000 after purchasing an additional 76,410 shares in the last quarter. Robbins Farley raised its holdings in shares of Alphabet by 0.8% in the fourth quarter. Robbins Farley now owns 15,006 shares of the information services provider’s stock worth $2,096,000 after buying an additional 118 shares during the last quarter. Quantum Financial Advisors LLC grew its holdings in shares of Alphabet by 8.0% during the third quarter. Quantum Financial Advisors LLC now owns 7,623 shares of the information services provider’s stock valued at $998,000 after buying an additional 564 shares during the last quarter. Finally, Colton Groome Financial Advisors LLC lifted its position in Alphabet by 3.8% during the 4th quarter. Colton Groome Financial Advisors LLC now owns 2,700 shares of the information services provider’s stock worth $377,000 after acquiring an additional 100 shares during the period. 40.03% of the stock is owned by institutional investors and hedge funds. Insider Activity at Alphabet In related news, Director John L. Hennessy sold 300 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $139.51, for a total transaction of $41,853.00. Following the completion of the transaction, the director now owns 9,291 shares of the company’s stock, valued at approximately $1,296,187.41. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider John Kent Walker sold 48,076 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $142.20, for a total value of $6,836,407.20. Following the completion of the transaction, the insider now owns 12,725 shares of the company’s stock, valued at $1,809,495. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director John L. Hennessy sold 300 shares of the company’s stock in a transaction that occurred on Tuesday, March 12th. The stock was sold at an average price of $139.51, for a total transaction of $41,853.00. Following the sale, the director now directly owns 9,291 shares in the company, valued at $1,296,187.41. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 276,511 shares of company stock worth $41,234,695. Company insiders own 0.88% of the company’s stock. Alphabet Stock Up 1.1 % Shares of NASDAQ:GOOGL opened at $176.06 on Monday. Alphabet Inc. has a 52-week low of $115.35 and a 52-week high of $176.26. The company has a quick ratio of 2.15, a current ratio of 2.15 and a debt-to-equity ratio of 0.05. The business has a fifty day moving average of $157.22 and a two-hundred day moving average of $145.29. The stock has a market cap of $2.18 trillion, a P/E ratio of 27.00, a PEG ratio of 1.35 and a beta of 1.02. Alphabet (NASDAQ:GOOGL – Get Free Report) last issued its earnings results on Thursday, April 25th. The information services provider reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.40. Alphabet had a net margin of 25.90% and a return on equity of 29.52%. The company had revenue of $80.54 billion for the quarter, compared to the consensus estimate of $66.04 billion. During the same period in the previous year, the firm earned $1.17 earnings per share. On average, research analysts expect that Alphabet Inc. will post 7.61 earnings per share for the current year. Alphabet Announces Dividend The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 17th. Investors of record on Monday, June 10th will be given a dividend of $0.20 per share. This represents a $0.80 dividend on an annualized basis and a dividend yield of 0.45%. The ex-dividend date of this dividend is Monday, June 10th. Alphabet’s payout ratio is 12.27%. Wall Street Analyst Weigh In A number of research analysts have recently weighed in on the company. JMP Securities reissued a “market outperform” rating and issued a $200.00 price objective on shares of Alphabet in a report on Wednesday, May 15th. Argus upped their price target on shares of Alphabet from $170.00 to $200.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Roth Mkm lifted their price objective on Alphabet from $164.00 to $202.00 and gave the company a “buy” rating in a research note on Friday, April 26th. KeyCorp upped their target price on Alphabet from $165.00 to $175.00 and gave the stock an “overweight” rating in a research note on Monday, April 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating and set a $215.00 price target on shares of Alphabet in a research report on Wednesday, May 15th. Five research analysts have rated the stock with a hold rating, thirty have given a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $190.60. Read Our Latest Analysis on Alphabet About Alphabet (Free Report) Alphabet Inc offers various products and platforms in the United States, Europe, the Middle East, Africa, the Asia-Pacific, Canada, and Latin America. It operates through Google Services, Google Cloud, and Other Bets segments. The Google Services segment provides products and services, including ads, Android, Chrome, devices, Gmail, Google Drive, Google Maps, Google Photos, Google Play, Search, and YouTube.

Charles Schwab Investment Management Inc. lowered its position in Robinhood Markets, Inc. (NASDAQ:HOOD – Free Report) by 1.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,265,863 shares of the company’s stock after selling 44,577 shares during the quarter. Charles Schwab Investment Management Inc. owned 0.38% of Robinhood Markets worth $41,607,000 as of its most recent SEC filing. Other institutional investors also recently modified their holdings of the company. Spire Wealth Management acquired a new position in shares of Robinhood Markets in the fourth quarter valued at $26,000. UniSuper Management Pty Ltd acquired a new position in shares of Robinhood Markets in the 3rd quarter valued at $30,000. Whittier Trust Co. lifted its holdings in shares of Robinhood Markets by 100.0% during the 4th quarter. Whittier Trust Co. now owns 4,634 shares of the company’s stock worth $59,000 after acquiring an additional 2,317 shares during the period. Financial Connections Group Inc. acquired a new stake in shares of Robinhood Markets during the 4th quarter valued at about $89,000. Finally, International Assets Investment Management LLC increased its stake in Robinhood Markets by 1,174.1% in the fourth quarter. International Assets Investment Management LLC now owns 7,326 shares of the company’s stock valued at $93,000 after acquiring an additional 6,751 shares during the period. Institutional investors and hedge funds own 93.27% of the company’s stock. Wall Street Analyst Weigh In A number of equities research analysts have weighed in on HOOD shares. JMP Securities reaffirmed a “market outperform” rating and set a $30.00 price objective on shares of Robinhood Markets in a report on Thursday. TheStreet upgraded Robinhood Markets from a “d+” rating to a “c-” rating in a research note on Wednesday, February 28th. JPMorgan Chase & Co. boosted their target price on shares of Robinhood Markets from $10.00 to $12.00 and gave the company an “underweight” rating in a research note on Wednesday, February 14th. Needham & Company LLC reiterated a “hold” rating on shares of Robinhood Markets in a research report on Monday, May 6th. Finally, KeyCorp boosted their price target on shares of Robinhood Markets from $22.00 to $23.00 and gave the company an “overweight” rating in a research report on Monday, April 22nd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $19.75. View Our Latest Report on HOOD Robinhood Markets Stock Up 12.2 % HOOD stock opened at $20.09 on Monday. Robinhood Markets, Inc. has a twelve month low of $7.91 and a twelve month high of $20.55. The company has a market cap of $17.66 billion, a P/E ratio of 133.93 and a beta of 1.74. The business has a fifty day moving average of $18.01 and a 200-day moving average of $13.86. Robinhood Markets (NASDAQ:HOOD – Get Free Report) last released its earnings results on Wednesday, May 8th. The company reported $0.18 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.13. The company had revenue of $618.00 million for the quarter, compared to the consensus estimate of $552.74 million. Robinhood Markets had a net margin of 6.22% and a return on equity of 1.86%. The company’s revenue was up 40.1% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.57) EPS. As a group, equities research analysts anticipate that Robinhood Markets, Inc. will post 0.53 earnings per share for the current fiscal year. Insider Activity at Robinhood Markets In other Robinhood Markets news, CEO Vladimir Tenev sold 500,000 shares of the company’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $15.12, for a total transaction of $7,560,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In related news, CEO Vladimir Tenev sold 500,000 shares of Robinhood Markets stock in a transaction on Monday, February 26th. The stock was sold at an average price of $15.12, for a total transaction of $7,560,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Jason Warnick sold 5,000 shares of the company’s stock in a transaction dated Friday, March 1st. The shares were sold at an average price of $16.47, for a total value of $82,350.00. Following the completion of the sale, the chief financial officer now owns 971,497 shares of the company’s stock, valued at approximately $16,000,555.59. The disclosure for this sale can be found here. Insiders have sold 2,577,873 shares of company stock worth $41,719,157 over the last ninety days. Company insiders own 20.81% of the company’s stock. Robinhood Markets Profile (Free Report) Robinhood Markets, Inc operates financial services platform in the United States. Its platform allows users to invest in stocks, exchange-traded funds (ETFs), American depository receipts, options, gold, and cryptocurrencies. The company offers fractional trading, recurring investments, fully-paid securities lending, access to investing on margin, cash sweep, instant withdrawals, retirement program, around-the-clock trading, and initial public offerings participation services.

Envestnet Portfolio Solutions Inc. increased its position in Zillow Group, Inc. (NASDAQ:ZG – Free Report) by 18.1% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 16,129 shares of the technology company’s stock after acquiring an additional 2,470 shares during the period. Envestnet Portfolio Solutions Inc.’s holdings in Zillow Group were worth $915,000 as of its most recent SEC filing. Several other hedge funds have also recently bought and sold shares of the company. Versor Investments LP raised its position in Zillow Group by 36.3% during the fourth quarter. Versor Investments LP now owns 13,897 shares of the technology company’s stock worth $788,000 after acquiring an additional 3,700 shares during the last quarter. New York Life Investment Management LLC increased its stake in shares of Zillow Group by 6.7% during the 4th quarter. New York Life Investment Management LLC now owns 6,365 shares of the technology company’s stock worth $361,000 after purchasing an additional 401 shares in the last quarter. Kestra Private Wealth Services LLC acquired a new position in shares of Zillow Group during the 4th quarter worth approximately $226,000. Hartline Investment Corp lifted its stake in Zillow Group by 9.7% in the 4th quarter. Hartline Investment Corp now owns 52,491 shares of the technology company’s stock valued at $2,977,000 after buying an additional 4,624 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new stake in Zillow Group during the 4th quarter valued at $26,000. 20.32% of the stock is owned by hedge funds and other institutional investors. Insider Transactions at Zillow Group In related news, Director Amy Bohutinsky sold 93,750 shares of Zillow Group stock in a transaction on Monday, March 4th. The shares were sold at an average price of $56.69, for a total transaction of $5,314,687.50. Following the transaction, the director now owns 5,652 shares in the company, valued at approximately $320,411.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, General Counsel Bradley D. Owens sold 1,373 shares of Zillow Group stock in a transaction that occurred on Wednesday, May 15th. The shares were sold at an average price of $44.15, for a total transaction of $60,617.95. Following the sale, the general counsel now owns 40,194 shares in the company, valued at $1,774,565.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Amy Bohutinsky sold 93,750 shares of the business’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $56.69, for a total transaction of $5,314,687.50. Following the transaction, the director now directly owns 5,652 shares in the company, valued at $320,411.88. The disclosure for this sale can be found here. Insiders sold 166,560 shares of company stock valued at $8,829,931 over the last 90 days. Corporate insiders own 17.14% of the company’s stock. Zillow Group Trading Down 1.3 % ZG opened at $43.35 on Monday. Zillow Group, Inc. has a 1 year low of $33.23 and a 1 year high of $59.23. The firm has a 50 day moving average price of $45.19 and a 200 day moving average price of $48.02. The company has a debt-to-equity ratio of 0.21, a current ratio of 3.32 and a quick ratio of 3.32. Wall Street Analysts Forecast Growth A number of equities analysts have recently weighed in on the company. DA Davidson reissued a “buy” rating and issued a $63.00 price target on shares of Zillow Group in a report on Friday, April 5th. Benchmark restated a “buy” rating and issued a $60.00 target price on shares of Zillow Group in a report on Tuesday, April 30th. Susquehanna raised their price target on shares of Zillow Group from $36.00 to $60.00 and gave the stock a “neutral” rating in a research note on Thursday, February 15th. JMP Securities cut their price objective on shares of Zillow Group from $68.00 to $62.00 and set a “market outperform” rating for the company in a research report on Thursday, May 2nd. Finally, JPMorgan Chase & Co. decreased their target price on shares of Zillow Group from $65.00 to $61.00 and set an “overweight” rating on the stock in a research report on Thursday, May 2nd. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and ten have given a buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $57.40. Read Our Latest Report on Zillow Group Zillow Group Company Profile (Free Report) Zillow Group, Inc operates real estate brands in mobile applications and Websites in the United States. The company offers premier agent and rentals marketplaces, new construction marketplaces, advertising, display advertising, and business technology solutions, as well as dotloop and floor plans. It also provides mortgage originations and the sale of mortgages, and advertising to mortgage lenders and other mortgage professionals; and title and escrow services.

Foundations Investment Advisors LLC trimmed its holdings in Independence Realty Trust, Inc. (NYSE:IRT – Free Report) by 6.4% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 14,375 shares of the real estate investment trust’s stock after selling 986 shares during the quarter. Foundations Investment Advisors LLC’s holdings in Independence Realty Trust were worth $215,000 as of its most recent SEC filing. A number of other institutional investors have also added to or reduced their stakes in the stock. Mirae Asset Global Investments Co. Ltd. grew its stake in Independence Realty Trust by 6.6% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 131,254 shares of the real estate investment trust’s stock valued at $1,847,000 after acquiring an additional 8,082 shares in the last quarter. Daiwa Securities Group Inc. grew its position in shares of Independence Realty Trust by 4.0% during the third quarter. Daiwa Securities Group Inc. now owns 71,603 shares of the real estate investment trust’s stock valued at $1,007,000 after purchasing an additional 2,782 shares in the last quarter. Nisa Investment Advisors LLC grew its position in shares of Independence Realty Trust by 3.7% during the third quarter. Nisa Investment Advisors LLC now owns 121,465 shares of the real estate investment trust’s stock valued at $1,709,000 after purchasing an additional 4,301 shares in the last quarter. California Public Employees Retirement System increased its holdings in shares of Independence Realty Trust by 13.9% in the third quarter. California Public Employees Retirement System now owns 417,793 shares of the real estate investment trust’s stock worth $5,878,000 after purchasing an additional 50,830 shares during the last quarter. Finally, Victory Capital Management Inc. boosted its stake in Independence Realty Trust by 5.5% during the third quarter. Victory Capital Management Inc. now owns 119,773 shares of the real estate investment trust’s stock valued at $1,685,000 after buying an additional 6,224 shares during the last quarter. 88.25% of the stock is owned by hedge funds and other institutional investors. Wall Street Analyst Weigh In Several analysts have recently issued reports on IRT shares. Deutsche Bank Aktiengesellschaft began coverage on Independence Realty Trust in a report on Tuesday, January 30th. They set a “buy” rating and a $18.00 price objective on the stock. JMP Securities lifted their price target on Independence Realty Trust from $15.00 to $17.00 and gave the stock a “market outperform” rating in a research report on Wednesday, March 6th. Royal Bank of Canada upped their price objective on Independence Realty Trust from $16.00 to $17.00 and gave the company an “outperform” rating in a research report on Friday, February 16th. TheStreet cut Independence Realty Trust from a “c” rating to a “d+” rating in a report on Friday, March 1st. Finally, Barclays decreased their price target on Independence Realty Trust from $22.00 to $18.00 and set an “overweight” rating on the stock in a report on Tuesday, February 20th. Two investment analysts have rated the stock with a sell rating and four have given a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $17.00. Get Our Latest Analysis on IRT Independence Realty Trust Price Performance Shares of NYSE:IRT opened at $17.11 on Monday. The firm has a market capitalization of $3.85 billion, a PE ratio of -570.14, a price-to-earnings-growth ratio of 2.51 and a beta of 1.07. The business has a 50 day simple moving average of $16.05 and a two-hundred day simple moving average of $15.16. Independence Realty Trust, Inc. has a 1 year low of $11.61 and a 1 year high of $18.77. Independence Realty Trust Announces Dividend The firm also recently announced a quarterly dividend, which was paid on Friday, April 19th. Shareholders of record on Friday, March 29th were paid a $0.16 dividend. The ex-dividend date of this dividend was Wednesday, March 27th. This represents a $0.64 dividend on an annualized basis and a yield of 3.74%. Independence Realty Trust’s payout ratio is -2,132.62%. Independence Realty Trust Company Profile (Free Report) Independence Realty Trust, Inc (NYSE: IRT) is a real estate investment trust that owns and operates multifamily communities, across non-gateway U.S. markets including Atlanta, GA, Dallas, TX, Denver, CO, Columbus, OH, Indianapolis, IN, Raleigh-Durham, NC, Oklahoma City, OK, Nashville, TN, Houston, TX, and Tampa, FL.

Charles Schwab Investment Management Inc. grew its holdings in shares of AGNC Investment Corp. (NASDAQ:AGNC – Free Report) by 13.1% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 4,319,163 shares of the real estate investment trust’s stock after purchasing an additional 500,145 shares during the quarter. Charles Schwab Investment Management Inc. owned approximately 0.64% of AGNC Investment worth $42,371,000 at the end of the most recent quarter. A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Portside Wealth Group LLC raised its position in shares of AGNC Investment by 8.8% in the 4th quarter. Portside Wealth Group LLC now owns 14,124 shares of the real estate investment trust’s stock worth $139,000 after buying an additional 1,147 shares during the period. Waterfront Wealth Inc. lifted its stake in shares of AGNC Investment by 2.5% in the 4th quarter. Waterfront Wealth Inc. now owns 52,215 shares of the real estate investment trust’s stock valued at $512,000 after purchasing an additional 1,251 shares in the last quarter. Consolidated Portfolio Review Corp grew its holdings in shares of AGNC Investment by 2.3% during the 4th quarter. Consolidated Portfolio Review Corp now owns 59,930 shares of the real estate investment trust’s stock worth $588,000 after purchasing an additional 1,341 shares during the period. Foster Victor Wealth Advisors LLC increased its position in AGNC Investment by 4.1% during the 4th quarter. Foster Victor Wealth Advisors LLC now owns 35,286 shares of the real estate investment trust’s stock worth $351,000 after purchasing an additional 1,379 shares in the last quarter. Finally, Norden Group LLC raised its holdings in AGNC Investment by 8.8% in the fourth quarter. Norden Group LLC now owns 17,089 shares of the real estate investment trust’s stock valued at $168,000 after buying an additional 1,387 shares during the period. Hedge funds and other institutional investors own 38.28% of the company’s stock. Insider Transactions at AGNC Investment In other AGNC Investment news, CFO Bernice Bell sold 3,500 shares of AGNC Investment stock in a transaction on Thursday, May 2nd. The stock was sold at an average price of $9.32, for a total transaction of $32,620.00. Following the sale, the chief financial officer now owns 309,973 shares of the company’s stock, valued at approximately $2,888,948.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, Director Frances Spark sold 5,000 shares of AGNC Investment stock in a transaction dated Wednesday, April 24th. The stock was sold at an average price of $9.35, for a total transaction of $46,750.00. Following the transaction, the director now directly owns 75,545 shares of the company’s stock, valued at $706,345.75. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CFO Bernice Bell sold 3,500 shares of AGNC Investment stock in a transaction that occurred on Thursday, May 2nd. The stock was sold at an average price of $9.32, for a total transaction of $32,620.00. Following the completion of the transaction, the chief financial officer now directly owns 309,973 shares in the company, valued at approximately $2,888,948.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 15,900 shares of company stock worth $149,030. Company insiders own 0.52% of the company’s stock. Wall Street Analysts Forecast Growth A number of analysts recently weighed in on AGNC shares. Royal Bank of Canada decreased their price target on shares of AGNC Investment from $11.00 to $10.00 and set an “outperform” rating for the company in a research report on Thursday, January 25th. Compass Point began coverage on AGNC Investment in a research note on Tuesday, February 20th. They issued a “buy” rating and a $10.25 target price for the company. JMP Securities restated a “market perform” rating on shares of AGNC Investment in a report on Thursday, April 18th. Keefe, Bruyette & Woods dropped their price objective on shares of AGNC Investment from $10.00 to $9.50 and set an “outperform” rating on the stock in a research note on Wednesday, April 24th. Finally, Jonestrading decreased their target price on shares of AGNC Investment from $10.75 to $10.25 and set a “buy” rating for the company in a research note on Tuesday, April 23rd. Four research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $9.79. Get Our Latest Stock Report on AGNC Investment AGNC Investment Price Performance Shares of AGNC opened at $9.90 on Monday. The company has a debt-to-equity ratio of 0.01, a current ratio of 0.28 and a quick ratio of 0.28. The company has a market cap of $7.20 billion, a P/E ratio of 10.88 and a beta of 1.45. AGNC Investment Corp. has a 12 month low of $6.81 and a 12 month high of $10.64. The stock has a fifty day moving average price of $9.55 and a 200 day moving average price of $9.44. AGNC Investment (NASDAQ:AGNC – Get Free Report) last released its quarterly earnings results on Tuesday, April 23rd. The real estate investment trust reported $0.58 EPS for the quarter, topping the consensus estimate of $0.56 by $0.02. The business had revenue of $642.00 million during the quarter, compared to analyst estimates of $568.38 million. AGNC Investment had a net margin of 32.12% and a return on equity of 27.14%. During the same quarter in the prior year, the firm earned $0.70 earnings per share. On average, research analysts forecast that AGNC Investment Corp. will post 2.1 earnings per share for the current year. AGNC Investment Dividend Announcement The firm also recently disclosed a may 24 dividend, which will be paid on Tuesday, June 11th. Stockholders of record on Friday, May 31st will be given a dividend of $0.12 per share. The ex-dividend date is Friday, May 31st. This represents a dividend yield of 14.9%. AGNC Investment’s dividend payout ratio is presently 158.24%. AGNC Investment Company Profile (Free Report) AGNC Investment Corp., formerly American Capital Agency Corp., is a real estate investment trust. The Company invests in agency residential mortgage-backed securities on a leveraged basis. Its investments consist of residential mortgage pass-through securities and collateralized mortgage obligations (CMOs) for which the principal and interest payments are guaranteed by a government-sponsored enterprise, such as the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac), or by the United States Government agency, such as the Government National Mortgage Association (Ginnie Mae) (collectively, GSEs). See Also Five stocks we like better than AGNC Investment How to Invest in Biotech Stocks MarketBeat Week in Review – 5/13 – 5/17 What is a buyback in stocks? A comprehensive guide for investors Take-Two Interactive Software Offers 2nd Chance for Investors What does consumer price index measure? Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

National Bank of Canada FI lessened its stake in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 668 shares of the company’s stock after selling 1,170 shares during the quarter. National Bank of Canada FI’s holdings in CRISPR Therapeutics were worth $44,000 as of its most recent filing with the SEC. Other large investors have also modified their holdings of the company. Vestmark Advisory Solutions Inc. acquired a new stake in CRISPR Therapeutics during the fourth quarter valued at approximately $10,848,000. Axxcess Wealth Management LLC lifted its stake in CRISPR Therapeutics by 16.2% during the fourth quarter. Axxcess Wealth Management LLC now owns 9,040 shares of the company’s stock worth $566,000 after purchasing an additional 1,259 shares during the last quarter. JFG Wealth Management LLC acquired a new position in CRISPR Therapeutics in the fourth quarter worth $220,000. Seaview Investment Managers LLC bought a new stake in CRISPR Therapeutics during the fourth quarter valued at $275,000. Finally, Mach 1 Financial Group LLC acquired a new stake in shares of CRISPR Therapeutics during the fourth quarter worth $441,000. Institutional investors own 69.20% of the company’s stock. Wall Street Analyst Weigh In CRSP has been the subject of a number of recent research reports. Chardan Capital boosted their price objective on shares of CRISPR Therapeutics from $110.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, February 22nd. Royal Bank of Canada increased their price target on CRISPR Therapeutics from $57.00 to $66.00 and gave the stock a “sector perform” rating in a research report on Thursday, February 22nd. JMP Securities reissued a “market outperform” rating and issued a $86.00 price target on shares of CRISPR Therapeutics in a report on Thursday, May 9th. Oppenheimer dropped their target price on CRISPR Therapeutics from $102.00 to $95.00 and set an “outperform” rating on the stock in a research report on Friday, May 10th. Finally, Robert W. Baird boosted their price target on shares of CRISPR Therapeutics from $46.00 to $52.00 and gave the company a “neutral” rating in a report on Thursday, May 9th. Three investment analysts have rated the stock with a sell rating, seven have assigned a hold rating and eight have given a buy rating to the company’s stock. According to MarketBeat.com, CRISPR Therapeutics currently has a consensus rating of “Hold” and a consensus price target of $73.93. View Our Latest Report on CRSP Insider Buying and Selling In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the transaction, the general counsel now owns 57,371 shares of the company’s stock, valued at approximately $4,570,747.57. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, General Counsel James R. Kasinger sold 1,913 shares of CRISPR Therapeutics stock in a transaction dated Tuesday, February 20th. The stock was sold at an average price of $79.67, for a total transaction of $152,408.71. Following the completion of the sale, the general counsel now directly owns 57,371 shares in the company, valued at approximately $4,570,747.57. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Samarth Kulkarni sold 6,370 shares of the firm’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $79.67, for a total transaction of $507,497.90. Following the transaction, the chief executive officer now directly owns 194,257 shares in the company, valued at approximately $15,476,455.19. The disclosure for this sale can be found here. In the last ninety days, insiders sold 63,992 shares of company stock valued at $4,525,135. Corporate insiders own 4.10% of the company’s stock. CRISPR Therapeutics Stock Performance Shares of NASDAQ:CRSP opened at $56.22 on Monday. The company has a market capitalization of $4.77 billion, a PE ratio of -20.67 and a beta of 1.80. The stock has a fifty day moving average of $62.11 and a 200-day moving average of $65.55. CRISPR Therapeutics AG has a one year low of $37.55 and a one year high of $91.10. CRISPR Therapeutics (NASDAQ:CRSP – Get Free Report) last posted its quarterly earnings data on Wednesday, May 8th. The company reported ($1.43) EPS for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.08). The business had revenue of $0.50 million for the quarter, compared to the consensus estimate of $25.53 million. The company’s quarterly revenue was down 99.5% on a year-over-year basis. During the same period in the previous year, the company earned ($0.67) earnings per share. As a group, research analysts forecast that CRISPR Therapeutics AG will post -5.64 EPS for the current fiscal year. CRISPR Therapeutics Profile (Free Report) CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.

Amalgamated Bank decreased its holdings in Encore Capital Group, Inc. (NASDAQ:ECPG – Free Report) by 2.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 8,867 shares of the asset manager’s stock after selling 236 shares during the period. Amalgamated Bank’s holdings in Encore Capital Group were worth $450,000 as of its most recent filing with the Securities & Exchange Commission. A number of other hedge funds also recently bought and sold shares of the stock. Illinois Municipal Retirement Fund raised its position in shares of Encore Capital Group by 2.2% in the 4th quarter. Illinois Municipal Retirement Fund now owns 13,683 shares of the asset manager’s stock worth $694,000 after acquiring an additional 301 shares in the last quarter. Rhumbline Advisers lifted its position in shares of Encore Capital Group by 0.6% during the third quarter. Rhumbline Advisers now owns 75,412 shares of the asset manager’s stock valued at $3,602,000 after buying an additional 469 shares during the last quarter. Sigma Planning Corp raised its stake in shares of Encore Capital Group by 6.0% during the 3rd quarter. Sigma Planning Corp now owns 13,302 shares of the asset manager’s stock worth $635,000 after acquiring an additional 756 shares in the last quarter. Swiss National Bank lifted its position in Encore Capital Group by 1.8% during the third quarter. Swiss National Bank now owns 51,700 shares of the asset manager’s stock valued at $2,469,000 after acquiring an additional 900 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank boosted its stake in Encore Capital Group by 30.4% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,705 shares of the asset manager’s stock valued at $272,000 after acquiring an additional 1,330 shares in the last quarter. Encore Capital Group Trading Up 0.8 % Shares of Encore Capital Group stock opened at $46.99 on Monday. Encore Capital Group, Inc. has a 12-month low of $34.74 and a 12-month high of $54.73. The firm’s 50 day simple moving average is $44.48 and its two-hundred day simple moving average is $46.85. The company has a current ratio of 0.96, a quick ratio of 0.96 and a debt-to-equity ratio of 3.53. The firm has a market capitalization of $1.11 billion, a price-to-earnings ratio of -5.48 and a beta of 1.38. Encore Capital Group (NASDAQ:ECPG – Get Free Report) last issued its earnings results on Wednesday, May 8th. The asset manager reported $0.95 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.94 by $0.01. Encore Capital Group had a positive return on equity of 9.95% and a negative net margin of 16.30%. The company had revenue of $328.39 million during the quarter, compared to analyst estimates of $330.83 million. During the same quarter last year, the business posted $0.94 EPS. The firm’s quarterly revenue was up 5.0% on a year-over-year basis. Analysts predict that Encore Capital Group, Inc. will post 5.59 EPS for the current year. Wall Street Analyst Weigh In A number of brokerages have recently issued reports on ECPG. JMP Securities reaffirmed a “market outperform” rating and set a $60.00 price target on shares of Encore Capital Group in a research report on Monday, May 6th. TheStreet lowered Encore Capital Group from a “c-” rating to a “d+” rating in a research report on Monday, March 18th. Get Our Latest Stock Analysis on Encore Capital Group Insider Activity In other news, insider Ryan B. Bell sold 5,500 shares of the stock in a transaction dated Friday, March 8th. The stock was sold at an average price of $50.00, for a total value of $275,000.00. Following the transaction, the insider now directly owns 42,404 shares of the company’s stock, valued at $2,120,200. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 2.90% of the company’s stock. Encore Capital Group Profile (Free Report) Encore Capital Group, Inc, a specialty finance company, provides debt recovery solutions and other related services for consumers across financial assets worldwide. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value, as well as manages them by working with individuals as they repay their obligations and works toward financial recovery. Read More Five stocks we like better than Encore Capital Group Canada Bond Market Holiday: How to Invest and Trade MarketBeat Week in Review – 5/13 – 5/17 Most Volatile Stocks, What Investors Need to Know Take-Two Interactive Software Offers 2nd Chance for Investors Investing in Travel Stocks Benefits Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

Amalgamated Bank lessened its holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT – Free Report) by 4.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 8,561 shares of the medical instruments supplier’s stock after selling 379 shares during the quarter. Amalgamated Bank’s holdings in LeMaitre Vascular were worth $486,000 at the end of the most recent reporting period. A number of other large investors have also modified their holdings of LMAT. Conestoga Capital Advisors LLC raised its position in shares of LeMaitre Vascular by 0.5% in the 4th quarter. Conestoga Capital Advisors LLC now owns 1,927,971 shares of the medical instruments supplier’s stock valued at $109,432,000 after purchasing an additional 10,390 shares during the last quarter. Vanguard Group Inc. raised its holdings in LeMaitre Vascular by 2.3% in the 3rd quarter. Vanguard Group Inc. now owns 1,510,567 shares of the medical instruments supplier’s stock worth $82,296,000 after purchasing an additional 33,500 shares during the period. Copeland Capital Management LLC boosted its position in LeMaitre Vascular by 2.3% during the fourth quarter. Copeland Capital Management LLC now owns 1,259,961 shares of the medical instruments supplier’s stock worth $71,515,000 after purchasing an additional 28,720 shares in the last quarter. Ranger Investment Management L.P. grew its holdings in LeMaitre Vascular by 15.8% in the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock valued at $48,968,000 after purchasing an additional 122,601 shares during the period. Finally, Russell Investments Group Ltd. increased its position in shares of LeMaitre Vascular by 6.7% in the fourth quarter. Russell Investments Group Ltd. now owns 288,212 shares of the medical instruments supplier’s stock valued at $16,359,000 after buying an additional 18,223 shares in the last quarter. Hedge funds and other institutional investors own 84.64% of the company’s stock. Analyst Ratings Changes LMAT has been the topic of a number of recent analyst reports. StockNews.com lowered LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. KeyCorp initiated coverage on shares of LeMaitre Vascular in a research note on Tuesday, February 6th. They set a “sector weight” rating for the company. Barrington Research raised their price target on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research note on Friday, May 3rd. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and boosted their price objective for the stock from $59.00 to $75.00 in a research note on Friday, April 26th. Finally, JMP Securities raised their target price on LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a research report on Friday, May 3rd. Three research analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $73.83. View Our Latest Research Report on LMAT LeMaitre Vascular Stock Performance NASDAQ:LMAT opened at $78.45 on Monday. LeMaitre Vascular, Inc. has a one year low of $44.27 and a one year high of $79.19. The stock has a market cap of $1.76 billion, a PE ratio of 51.95, a P/E/G ratio of 2.39 and a beta of 0.88. The stock has a 50 day moving average price of $67.83 and a 200 day moving average price of $60.79. LeMaitre Vascular (NASDAQ:LMAT – Get Free Report) last issued its earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.39 by $0.05. The business had revenue of $53.48 million during the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The company’s revenue for the quarter was up 13.6% on a year-over-year basis. During the same period last year, the company earned $0.27 EPS. As a group, analysts predict that LeMaitre Vascular, Inc. will post 1.78 earnings per share for the current fiscal year. LeMaitre Vascular Announces Dividend The company also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Stockholders of record on Thursday, May 16th will be paid a $0.16 dividend. The ex-dividend date of this dividend is Wednesday, May 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.82%. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%. Insider Transactions at LeMaitre Vascular In related news, Director David B. Roberts sold 5,025 shares of the company’s stock in a transaction that occurred on Monday, May 6th. The stock was sold at an average price of $75.62, for a total value of $379,990.50. Following the transaction, the director now directly owns 14,114 shares in the company, valued at $1,067,300.68. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director David B. Roberts sold 5,025 shares of the business’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.62, for a total value of $379,990.50. Following the sale, the director now directly owns 14,114 shares in the company, valued at approximately $1,067,300.68. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Lawrence J. Jasinski sold 5,110 shares of the stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $67.50, for a total transaction of $344,925.00. Following the transaction, the director now directly owns 5,309 shares of the company’s stock, valued at approximately $358,357.50. The disclosure for this sale can be found here. Insiders sold 195,967 shares of company stock worth $14,072,324 in the last 90 days. Insiders own 10.79% of the company’s stock. LeMaitre Vascular Company Profile (Free Report) LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature. Read More Five stocks we like better than LeMaitre Vascular Profitably Trade Stocks at 52-Week Highs MarketBeat Week in Review – 5/13 – 5/17 How to Invest in Tech Stocks and Top Tech Stocks to Consider Take-Two Interactive Software Offers 2nd Chance for Investors How to Know Which Cryptocurrency to Buy: A Guide for Investors Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook

Amalgamated Bank lowered its holdings in shares of PennyMac Mortgage Investment Trust (NYSE:PMT – Free Report) by 2.7% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 33,008 shares of the real estate investment trust’s stock after selling 906 shares during the quarter. Amalgamated Bank’s holdings in PennyMac Mortgage Investment Trust were worth $493,000 as of its most recent filing with the Securities & Exchange Commission. A number of other institutional investors and hedge funds have also made changes to their positions in PMT. Allspring Global Investments Holdings LLC raised its holdings in PennyMac Mortgage Investment Trust by 16.5% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 7,858 shares of the real estate investment trust’s stock valued at $97,000 after buying an additional 1,115 shares during the period. Essex Financial Services Inc. bought a new stake in shares of PennyMac Mortgage Investment Trust in the 4th quarter worth about $150,000. Kestra Private Wealth Services LLC purchased a new position in shares of PennyMac Mortgage Investment Trust during the 4th quarter worth about $183,000. Sherbrooke Park Advisers LLC bought a new position in PennyMac Mortgage Investment Trust during the 3rd quarter valued at about $157,000. Finally, Atria Wealth Solutions Inc. purchased a new stake in PennyMac Mortgage Investment Trust in the 4th quarter worth about $204,000. 67.38% of the stock is owned by hedge funds and other institutional investors. Wall Street Analysts Forecast Growth A number of research analysts have recently commented on the company. JMP Securities reaffirmed a “market outperform” rating and set a $15.00 target price on shares of PennyMac Mortgage Investment Trust in a research note on Thursday, April 18th. Piper Sandler reaffirmed a “neutral” rating and issued a $15.00 price objective (up previously from $14.50) on shares of PennyMac Mortgage Investment Trust in a research report on Thursday, May 9th. B. Riley lifted their target price on PennyMac Mortgage Investment Trust from $15.00 to $16.00 and gave the stock a “buy” rating in a research report on Wednesday, February 7th. Finally, Wedbush restated a “neutral” rating and issued a $15.00 price target on shares of PennyMac Mortgage Investment Trust in a report on Monday, April 29th. Five investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, PennyMac Mortgage Investment Trust currently has a consensus rating of “Hold” and an average target price of $14.92. Read Our Latest Stock Analysis on PennyMac Mortgage Investment Trust Insider Activity at PennyMac Mortgage Investment Trust In other PennyMac Mortgage Investment Trust news, Director Doug Jones sold 7,810 shares of the company’s stock in a transaction on Monday, March 11th. The stock was sold at an average price of $14.34, for a total transaction of $111,995.40. Following the completion of the sale, the director now owns 53,311 shares in the company, valued at $764,479.74. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 0.89% of the stock is currently owned by corporate insiders. PennyMac Mortgage Investment Trust Stock Down 0.9 % NYSE:PMT opened at $15.04 on Monday. The company has a debt-to-equity ratio of 1.37, a current ratio of 0.34 and a quick ratio of 0.34. PennyMac Mortgage Investment Trust has a 1-year low of $10.52 and a 1-year high of $15.89. The company has a 50-day moving average of $14.29 and a 200 day moving average of $14.32. The firm has a market cap of $1.31 billion, a PE ratio of 10.03 and a beta of 1.47. PennyMac Mortgage Investment Trust Announces Dividend The firm also recently disclosed a quarterly dividend, which was paid on Friday, April 26th. Stockholders of record on Friday, April 12th were paid a dividend of $0.40 per share. The ex-dividend date was Thursday, April 11th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 10.64%. PennyMac Mortgage Investment Trust’s dividend payout ratio is presently 106.67%. PennyMac Mortgage Investment Trust Company Profile (Free Report) PennyMac Mortgage Investment Trust, through its subsidiary, primarily invests in mortgage-related assets in the United States. The company operates through: Credit Sensitive Strategies, Interest Rate Sensitive Strategies, Correspondent Production segments. Its Credit Sensitive Strategies segment invests in credit risk transfer (CRT) agreements, CRT securities, subordinate mortgage-backed securities (MBS), distressed loans, and real estate.

Amalgamated Bank lessened its stake in shares of Getty Realty Corp. (NYSE:GTY – Free Report) by 3.6% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 17,358 shares of the real estate investment trust’s stock after selling 642 shares during the period. Amalgamated Bank’s holdings in Getty Realty were worth $507,000 at the end of the most recent reporting period. Several other institutional investors and hedge funds have also bought and sold shares of GTY. Commonwealth Equity Services LLC raised its holdings in shares of Getty Realty by 16.8% during the third quarter. Commonwealth Equity Services LLC now owns 10,230 shares of the real estate investment trust’s stock valued at $284,000 after purchasing an additional 1,469 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank raised its stake in Getty Realty by 12.4% during the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 17,299 shares of the real estate investment trust’s stock worth $480,000 after buying an additional 1,909 shares during the period. Allspring Global Investments Holdings LLC boosted its holdings in Getty Realty by 6.2% in the third quarter. Allspring Global Investments Holdings LLC now owns 10,491 shares of the real estate investment trust’s stock worth $291,000 after acquiring an additional 613 shares in the last quarter. Daiwa Securities Group Inc. grew its stake in Getty Realty by 5.9% in the third quarter. Daiwa Securities Group Inc. now owns 14,655 shares of the real estate investment trust’s stock valued at $406,000 after acquiring an additional 813 shares during the period. Finally, Nisa Investment Advisors LLC increased its holdings in shares of Getty Realty by 6.4% during the third quarter. Nisa Investment Advisors LLC now owns 23,108 shares of the real estate investment trust’s stock valued at $641,000 after acquiring an additional 1,380 shares in the last quarter. 85.11% of the stock is owned by institutional investors. Getty Realty Stock Down 0.1 % Shares of NYSE:GTY opened at $28.45 on Monday. The business’s 50 day moving average is $27.20 and its 200 day moving average is $27.91. Getty Realty Corp. has a 12-month low of $25.90 and a 12-month high of $35.56. The stock has a market cap of $1.54 billion, a price-to-earnings ratio of 24.32 and a beta of 0.88. The company has a quick ratio of 3.37, a current ratio of 3.37 and a debt-to-equity ratio of 0.84. Getty Realty (NYSE:GTY – Get Free Report) last posted its quarterly earnings data on Friday, April 26th. The real estate investment trust reported $0.30 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.27). The firm had revenue of $48.97 million for the quarter, compared to analysts’ expectations of $46.63 million. Getty Realty had a return on equity of 6.80% and a net margin of 32.74%. During the same period in the prior year, the firm earned $0.56 earnings per share. On average, sell-side analysts forecast that Getty Realty Corp. will post 2.31 earnings per share for the current fiscal year. Getty Realty Dividend Announcement The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Shareholders of record on Thursday, June 27th will be given a $0.45 dividend. This represents a $1.80 dividend on an annualized basis and a yield of 6.33%. The ex-dividend date is Thursday, June 27th. Getty Realty’s payout ratio is 153.85%. Analyst Ratings Changes Several analysts recently issued reports on the stock. StockNews.com raised shares of Getty Realty from a “sell” rating to a “hold” rating in a research report on Monday, April 22nd. JMP Securities reiterated a “market outperform” rating and set a $33.00 price objective on shares of Getty Realty in a report on Monday, March 25th. Get Our Latest Analysis on GTY Getty Realty Profile (Free Report)

Natixis Advisors L.P. purchased a new position in Arbor Realty Trust, Inc. (NYSE:ABR – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 14,368 shares of the real estate investment trust’s stock, valued at approximately $218,000. A number of other institutional investors and hedge funds have also recently bought and sold shares of the business. Sound Income Strategies LLC lifted its stake in Arbor Realty Trust by 322.1% in the 4th quarter. Sound Income Strategies LLC now owns 2,347 shares of the real estate investment trust’s stock worth $36,000 after purchasing an additional 1,791 shares in the last quarter. Anchor Investment Management LLC purchased a new position in Arbor Realty Trust during the fourth quarter worth approximately $41,000. Halpern Financial Inc. boosted its stake in Arbor Realty Trust by 601.8% during the fourth quarter. Halpern Financial Inc. now owns 3,509 shares of the real estate investment trust’s stock worth $52,000 after buying an additional 3,009 shares during the last quarter. PNC Financial Services Group Inc. grew its holdings in Arbor Realty Trust by 27.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 6,121 shares of the real estate investment trust’s stock valued at $93,000 after buying an additional 1,333 shares in the last quarter. Finally, Clearstead Advisors LLC acquired a new stake in shares of Arbor Realty Trust in the 3rd quarter worth $93,000. 57.25% of the stock is currently owned by institutional investors and hedge funds. Insider Buying and Selling In related news, Director William C. Green purchased 10,209 shares of Arbor Realty Trust stock in a transaction that occurred on Monday, March 18th. The stock was purchased at an average cost of $12.93 per share, with a total value of $132,002.37. Following the completion of the transaction, the director now directly owns 162,809 shares in the company, valued at $2,105,120.37. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 3.70% of the stock is owned by company insiders. Arbor Realty Trust Price Performance Shares of ABR opened at $13.89 on Monday. The firm has a market capitalization of $2.62 billion, a price-to-earnings ratio of 8.63 and a beta of 1.96. The firm’s fifty day simple moving average is $13.01 and its 200-day simple moving average is $13.45. Arbor Realty Trust, Inc. has a twelve month low of $11.77 and a twelve month high of $17.74. The company has a current ratio of 36.63, a quick ratio of 36.63 and a debt-to-equity ratio of 3.14. Arbor Realty Trust Announces Dividend The firm also recently announced a quarterly dividend, which will be paid on Friday, May 31st. Stockholders of record on Friday, May 17th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 12.38%. The ex-dividend date of this dividend is Thursday, May 16th. Arbor Realty Trust’s dividend payout ratio (DPR) is presently 106.83%. Analyst Upgrades and Downgrades ABR has been the topic of a number of analyst reports. TheStreet raised shares of Arbor Realty Trust from a “d+” rating to a “c” rating in a research note on Monday, March 18th. Keefe, Bruyette & Woods cut their target price on Arbor Realty Trust from $13.50 to $13.25 and set a “market perform” rating for the company in a research note on Wednesday, April 10th. JPMorgan Chase & Co. reduced their price objective on shares of Arbor Realty Trust from $12.50 to $12.00 and set an “underweight” rating on the stock in a report on Wednesday, April 10th. JMP Securities reduced their price target on shares of Arbor Realty Trust from $19.00 to $17.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 1st. Finally, Wedbush restated a “neutral” rating and set a $13.00 price target on shares of Arbor Realty Trust in a research note on Monday, May 6th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $14.71. View Our Latest Research Report on ABR Arbor Realty Trust Company Profile (Free Report) Arbor Realty Trust, Inc invests in a diversified portfolio of structured finance assets in the multifamily, single-family rental, and commercial real estate markets in the United States. The company operates through Structured Business and Agency Business segments. It primarily invests in bridge and mezzanine loans, including junior participating interests in first mortgages, and preferred and direct equity, as well as real estate-related joint ventures, real estate-related notes, and various mortgage-related securities.

Natixis Advisors L.P. trimmed its position in Two Harbors Investment Corp. (NYSE:TWO – Free Report) by 91.7% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 18,522 shares of the real estate investment trust’s stock after selling 204,626 shares during the quarter. Natixis Advisors L.P.’s holdings in Two Harbors Investment were worth $258,000 as of its most recent filing with the Securities and Exchange Commission. Several other large investors have also modified their holdings of TWO. Zurcher Kantonalbank Zurich Cantonalbank boosted its holdings in Two Harbors Investment by 30.7% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,611 shares of the real estate investment trust’s stock valued at $273,000 after acquiring an additional 4,837 shares during the period. Nisa Investment Advisors LLC lifted its position in shares of Two Harbors Investment by 5.4% during the 3rd quarter. Nisa Investment Advisors LLC now owns 36,564 shares of the real estate investment trust’s stock worth $484,000 after purchasing an additional 1,872 shares during the last quarter. Jump Financial LLC bought a new stake in Two Harbors Investment during the 3rd quarter valued at approximately $227,000. Swiss National Bank grew its holdings in Two Harbors Investment by 1.0% in the 3rd quarter. Swiss National Bank now owns 212,488 shares of the real estate investment trust’s stock valued at $2,813,000 after buying an additional 2,000 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA increased its position in Two Harbors Investment by 1.2% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 2,227,050 shares of the real estate investment trust’s stock worth $29,486,000 after buying an additional 26,801 shares during the period. 64.19% of the stock is owned by institutional investors. Two Harbors Investment Stock Up 0.4 % TWO opened at $13.03 on Monday. Two Harbors Investment Corp. has a fifty-two week low of $9.83 and a fifty-two week high of $14.59. The company has a debt-to-equity ratio of 0.99, a current ratio of 1.09 and a quick ratio of 1.09. The firm’s fifty day moving average price is $12.67 and its two-hundred day moving average price is $13.14. The company has a market capitalization of $1.35 billion, a P/E ratio of 7.32 and a beta of 1.85. Two Harbors Investment Announces Dividend The company also recently announced a quarterly dividend, which was paid on Monday, April 29th. Stockholders of record on Thursday, April 4th were paid a $0.45 dividend. The ex-dividend date of this dividend was Wednesday, April 3rd. This represents a $1.80 annualized dividend and a dividend yield of 13.81%. Two Harbors Investment’s dividend payout ratio is presently 101.12%. Analyst Ratings Changes Several brokerages have recently issued reports on TWO. JPMorgan Chase & Co. lowered their price objective on shares of Two Harbors Investment from $13.50 to $12.50 and set a “neutral” rating on the stock in a research note on Wednesday, April 10th. Jonestrading started coverage on shares of Two Harbors Investment in a research report on Friday, March 22nd. They set a “hold” rating for the company. TheStreet downgraded Two Harbors Investment from a “c-” rating to a “d” rating in a research report on Tuesday, January 30th. StockNews.com raised Two Harbors Investment from a “sell” rating to a “hold” rating in a report on Wednesday, May 1st. Finally, JMP Securities restated a “market outperform” rating and set a $15.00 price objective on shares of Two Harbors Investment in a research report on Thursday, April 18th. Eight investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $14.57. View Our Latest Stock Report on Two Harbors Investment About Two Harbors Investment (Free Report) Two Harbors Investment Corp. invests in, finances, and manages mortgage servicing rights (MSRs), agency residential mortgage-backed securities (RMBS), and other financial assets through RoundPoint in the United States. The company target assets include agency RMBS collateralized by fixed rate mortgage loans, adjustable rate mortgage loans, hybrid mortgage loans, or derivatives; and other assets, such as financial and mortgage-related assets, including non-agency securities and non-hedging transactions. Read More Five stocks we like better than Two Harbors Investment Do Real Estate Investment Trusts Deserve a Place in Your Portfolio? MarketBeat Week in Review – 5/13 – 5/17 Breakout Stocks: What They Are and How to Identify Them Take-Two Interactive Software Offers 2nd Chance for Investors Where to Find Earnings Call Transcripts Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook Want to see what other hedge funds are holding TWO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Two Harbors Investment Corp. (NYSE:TWO – Free Report).

Natixis Advisors L.P. bought a new position in shares of MacroGenics, Inc. (NASDAQ:MGNX – Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 30,892 shares of the biopharmaceutical company’s stock, valued at approximately $297,000. Other institutional investors have also modified their holdings of the company. China Universal Asset Management Co. Ltd. increased its position in shares of MacroGenics by 349.2% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 7,174 shares of the biopharmaceutical company’s stock worth $69,000 after acquiring an additional 5,577 shares during the period. SG Americas Securities LLC purchased a new position in shares of MacroGenics during the third quarter worth approximately $97,000. Sherbrooke Park Advisers LLC purchased a new position in shares of MacroGenics during the third quarter worth approximately $99,000. WINTON GROUP Ltd bought a new position in shares of MacroGenics during the third quarter valued at approximately $147,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of MacroGenics during the third quarter valued at approximately $281,000. 96.89% of the stock is owned by hedge funds and other institutional investors. MacroGenics Stock Down 14.8 % Shares of MGNX opened at $4.36 on Monday. The company has a market cap of $273.07 million, a price-to-earnings ratio of -11.19 and a beta of 2.09. MacroGenics, Inc. has a twelve month low of $3.14 and a twelve month high of $21.88. The company has a 50 day moving average of $14.44 and a two-hundred day moving average of $12.70. MacroGenics (NASDAQ:MGNX – Get Free Report) last posted its quarterly earnings results on Thursday, May 9th. The biopharmaceutical company reported ($0.84) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.17). The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $13.63 million. MacroGenics had a negative return on equity of 98.01% and a negative net margin of 53.60%. On average, sell-side analysts expect that MacroGenics, Inc. will post -3.04 EPS for the current year. Insiders Place Their Bets In other MacroGenics news, VP Jeffrey Stuart Peters sold 51,395 shares of the firm’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $15.55, for a total value of $799,192.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 11.30% of the company’s stock. Wall Street Analyst Weigh In A number of equities analysts have recently issued reports on MGNX shares. JMP Securities dropped their price objective on shares of MacroGenics from $22.00 to $16.00 and set a “market outperform” rating on the stock in a research note on Friday, May 10th. HC Wainwright dropped their price objective on shares of MacroGenics from $16.00 to $4.00 and set a “neutral” rating on the stock in a research note on Monday, May 13th. Barclays dropped their price objective on shares of MacroGenics from $25.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, May 10th. B. Riley started coverage on shares of MacroGenics in a research note on Friday, April 26th. They set a “buy” rating and a $25.00 price objective on the stock. Finally, TD Cowen downgraded shares of MacroGenics from a “buy” rating to a “hold” rating in a research note on Friday, May 10th. Five investment analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $13.67. View Our Latest Stock Report on MacroGenics MacroGenics Company Profile (Free Report) MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.

Natixis Advisors L.P. bought a new stake in shares of Avanos Medical, Inc. (NYSE:AVNS – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 14,142 shares of the company’s stock, valued at approximately $317,000. A number of other hedge funds and other institutional investors also recently made changes to their positions in AVNS. William Blair Investment Management LLC purchased a new position in shares of Avanos Medical in the 3rd quarter valued at approximately $22,134,000. RGM Capital LLC lifted its position in Avanos Medical by 6.8% during the third quarter. RGM Capital LLC now owns 2,951,691 shares of the company’s stock valued at $59,683,000 after buying an additional 189,017 shares during the period. Foundry Partners LLC boosted its holdings in shares of Avanos Medical by 74.6% during the 4th quarter. Foundry Partners LLC now owns 371,029 shares of the company’s stock valued at $8,322,000 after buying an additional 158,473 shares in the last quarter. Kestrel Investment Management Corp purchased a new stake in shares of Avanos Medical in the 4th quarter worth about $3,265,000. Finally, Jupiter Asset Management Ltd. increased its stake in shares of Avanos Medical by 234.2% in the 3rd quarter. Jupiter Asset Management Ltd. now owns 149,983 shares of the company’s stock worth $3,033,000 after acquiring an additional 105,100 shares in the last quarter. Institutional investors own 95.17% of the company’s stock. Wall Street Analysts Forecast Growth Several equities research analysts recently commented on the stock. JMP Securities reissued a “market perform” rating on shares of Avanos Medical in a research note on Tuesday, May 7th. StockNews.com upgraded Avanos Medical from a “hold” rating to a “buy” rating in a research note on Saturday, May 11th. Two equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. Based on data from MarketBeat.com, Avanos Medical currently has an average rating of “Moderate Buy” and a consensus target price of $31.00. Read Our Latest Stock Report on Avanos Medical Insider Activity In related news, CFO Michael Greiner sold 8,000 shares of Avanos Medical stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $19.12, for a total transaction of $152,960.00. Following the transaction, the chief financial officer now directly owns 151,495 shares in the company, valued at $2,896,584.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 2.90% of the company’s stock. Avanos Medical Stock Performance Shares of AVNS stock opened at $20.39 on Monday. The company has a debt-to-equity ratio of 0.14, a quick ratio of 1.47 and a current ratio of 2.28. The company has a market capitalization of $935.98 million, a price-to-earnings ratio of -15.33 and a beta of 0.97. Avanos Medical, Inc. has a one year low of $17.24 and a one year high of $26.56. The company’s 50-day moving average is $19.34 and its 200 day moving average is $20.02. Avanos Medical (NYSE:AVNS – Get Free Report) last announced its quarterly earnings results on Thursday, May 2nd. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.21 by ($0.02). The firm had revenue of $166.10 million for the quarter, compared to the consensus estimate of $162.90 million. Avanos Medical had a negative net margin of 9.15% and a positive return on equity of 4.10%. Avanos Medical’s revenue was up 4.3% on a year-over-year basis. During the same period last year, the business earned $0.27 EPS. Sell-side analysts expect that Avanos Medical, Inc. will post 1.38 EPS for the current fiscal year. Avanos Medical Profile (Free Report) Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.